Sign in

Private company

Nascent Biotech Inc.

Nascent Biotech Inc. is an American pharmaceutical preparations company, incorporated in Nevada.1 It is headquartered in North Palm Beach, Florida.1

Last updated Oct 21, 2026.

Overview

-$2.1MNet income, fiscal 20242
  • IndustryPharmaceutical Preparations1
  • HeadquartersNorth Palm Beach, Florida1
  • Incorporated inNV3
  • Business address631 Us Hwy 1, Suite 407, North Palm Beach, Fl 334083
  • Filer category, Emerging growth company3

See how the biggest companies compare on our leaderboards

NASCENT BIOTECH INC., a Nevada corporation (“Nascent” or the “Company”), is actively developing its primary asset, Pritumumab, for the treatment of brain cancer and pancreatic cancer. Nascent is also actively researching other cancers that have a high probability of benefiting from the therapeutic effects of Pritumumab because they share a common molecular target. The Company continues exploring Pritumumab in its use against viruses. Nascent has completed its research with their partner, Manhattan BioSolutions developing a traditional vaccine platform to create vaccines for viral infections.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-100.0%Revenue growth, 20235

Financial statements

Revenue67895$0 in 2023
0$1.0M$2.0M$3.0M2017: $3.0M$3.0M20172019: $0$020192020: $0$020202021: $750.0K$750.0K20212022: $1.0M$1.0M2022+33%2023: $0$02023
Operating income61078952-$2.2M in 2023
-$4.0M-$2.0M0$2.0M2017: $1.4M$1.4M20172018: -$2.2M-$2.2M20182019: -$1.4M-$1.4M2019−38%2020: -$3.4M-$3.4M2020+152%2021: -$1.4M-$1.4M2021−59%2022: -$457.1K-$457.1K2022−67%2023: -$2.2M-$2.2M2023+372%
Net income61078952-$2.8M in 2023
-$6.0M-$4.0M-$2.0M0$2.0M2017: $1.1M$1.1M20172018: -$2.2M-$2.2M20182019: -$1.4M-$1.4M2019−38%2020: -$4.0M-$4.0M2020+193%2021: -$958.8K-$958.8K2021−76%2022: -$470.4K-$470.4K2022−51%2023: -$2.8M-$2.8M2023+495%
Fiscal year2017201820192020202120222023
Revenue$3.0M6$07$08$750.0K9$1.0M5$05
Research and development$486.9K6$1.2M10$254.0K7$293.7K8$321.9K9$197.4K5$270.5K2
Selling, general and admin$1.6M6$1.0M6
Operating expenses$1.5M5$2.2M2
Operating income$1.4M6-$2.2M10-$1.4M7-$3.4M8-$1.4M9-$457.1K5-$2.2M2
Interest$54.1K6$07$86.6K8$269.4K9$48.0K5$1.6M2
Income tax$240.0K6$07$07$09$05$02
Net income$1.1M6-$2.2M10-$1.4M7-$4.0M8-$958.8K9-$470.4K5-$2.8M2
Earnings per share$0.056-$0.096
Earnings per share (diluted)$0.056-$0.096

Compare Nascent Biotech Inc. with another company

Corporate structure

Nascent Biotech Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Nascent Biotech Inc.

  • YA II PN, Ltd. Filed SC 13G/A on Nascent Biotech Inc., latest Feb 13, 2024 (3 filings since Sep 1, 2022)
  • Robert David Burke Filed SC 13D on Nascent Biotech Inc., latest Apr 14, 2023
  • Nascent Biotech Inc. North Palm Beach, Florida

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Nascent Biotech Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Mark Glassy2014
  2. Sean Carrick2017–2024

President

  1. Sean Carrick2015–2024

Chief financial officer

  1. Lowell Thomas Holden2014–2024
201520202025
Board members and other officers (7)

Timeline

  1. Jan 17, 20258-K Executive or director change; Other events22
  2. Dec 19, 20238-K Other events23
  3. Sep 6, 20238-K Other events24
  4. Jul 14, 20238-K Other events25
  5. May 30, 20238-K Ended a material agreement; Other events26
  6. May 9, 20238-K Other events27
  7. Jan 26, 20238-K Other events28
  8. Sep 28, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares29
  9. Sep 20, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares30
  10. Sep 9, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares31
  11. Sep 9, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares32
  12. Sep 6, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares33
  13. Jan 9, 2017New chief executive Sean Carrick becomes CEO15
  14. Dec 31, 2014New chief executive Mark Glassy becomes CEO16

Filings

78 filings to the SEC since October 2021: 4 annual reports, 9 quarterly reports, 13 major events, 30 insider forms, 4 large holders, 18 other. The latest 20:

  1. Apr 1, 202515-12G EDGAR
  2. Jan 17, 20258-K EDGAR
  3. Nov 15, 2024NT 10-Q EDGAR
  4. Aug 14, 202410-Q EDGAR
  5. Jul 2, 20244 EDGAR
  6. Jul 2, 20244 EDGAR
  7. Jul 2, 20244 EDGAR
  8. Jul 1, 202410-K EDGAR
  9. Apr 10, 20244 EDGAR
  10. Apr 10, 20244 EDGAR
  11. Apr 10, 20244 EDGAR
  12. Apr 8, 2024EFFECT EDGAR
  13. Apr 5, 2024CORRESP EDGAR
  14. Apr 3, 2024CORRESP EDGAR
  15. Apr 3, 2024S-1/A EDGAR
  16. Apr 2, 2024UPLOAD EDGAR
  17. Mar 29, 2024CORRESP EDGAR
  18. Mar 29, 2024S-1/A EDGAR
  19. Mar 26, 2024UPLOAD EDGAR
  20. Mar 15, 2024S-1 EDGAR

The 78 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 3 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 7, 2023HOLDEN LOWELL THOMASCFOBuy130,000$0.04$5.2KForm 4
Jan 27, 2023HOLDEN LOWELL THOMASCFOBuy20,000$0.14$2.8KForm 4
Jan 27, 2023HOLDEN LOWELL THOMASCFOBuy20,000$0.14$2.8KForm 4
Jul 21, 2022HOLDEN LOWELL THOMASCFOSale5,000$0.26$1.3KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • YA II PN, Ltd.SC 13G/A, 3 filings Sep 1, 2022 to Feb 13, 202434
  • Robert David BurkeSC 13D, 1 filing Apr 14, 202335

SEC filer profile

How Nascent Biotech Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNascent Biotech Inc.1
  • CIK0001622057
  • Employer ID (EIN)45-06127151
  • Filer status<br>emerging growth company1
  • Incorporated inNevada1
  • Fiscal year endsMarch 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address631 Us Hwy 1, Suite 407, North Palm Beach, FL 334081
  • Phone612-961-56561
  • Shares outstanding172,202,165 as of Aug 14, 202413
  • Public float$19.2M as of Sep 30, 20232
  • On EDGAR sinceOct 10, 20141
  • Filings227 in all: 4 (81), 8-K (42), 10-Q (29), 10-K (10), CORRESP (9), UPLOAD (9), EFFECT (6), S-1/A (5)1
    All 25 form types

    3 (4), NT 10-K (4), NT 10-Q (4), S-1 (4), 4/A (3), 10-12G/A (2), 8-K/A (2), POS AM (2), SC 13G (2), SC 13G/A (2), 10-12G (1), 10-K/A (1), 15-12G (1), D (1), S-8 (1), S-8 POS (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Jul 1, 2024
    Quarterly report (10-Q) Aug 14, 2024
    Latest 8-K (8-K) Jan 17, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
    SEC EDGAROther events
  24. 24
    SEC EDGAROther events
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
    SEC EDGAROther events
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35